Analysts See $-0.38 EPS for Seattle Genetics, Inc. (SGEN)

Seattle Genetics, Inc. (NASDAQ:SGEN) Logo
Investors sentiment increased to 1.39 in Q3 2018. Its up 0.15, from 1.24 in 2018Q2. It increased, as 18 investors sold Seattle Genetics, Inc. shares while 76 reduced holdings. 58 funds opened positions while 73 raised stakes. 158.11 million shares or 1.19% less from 160.01 million shares in 2018Q2 were reported.
Zurcher Kantonalbank (Zurich Cantonalbank) holds 0.02% or 23,953 shares. 5,282 are held by Private Advisor Grp Ltd Liability Corporation. Royal Comml Bank Of Canada has invested 0.01% in Seattle Genetics, Inc. (NASDAQ:SGEN). First City Cap Management invested in 0.27% or 5,350 shares. 1,213 are held by Stratos Wealth Partners. One Trading Limited Partnership has invested 0% in Seattle Genetics, Inc. (NASDAQ:SGEN). 4,337 were reported by Comerica Bancorp. Platinum Investment Mgmt Ltd invested 0.08% in Seattle Genetics, Inc. (NASDAQ:SGEN). Castleark Management Ltd Co reported 0.12% in Seattle Genetics, Inc. (NASDAQ:SGEN). Great Lakes Ltd Liability Corporation owns 62,133 shares. University Of Notre Dame Du Lac holds 0.53% or 37,240 shares. Toronto Dominion National Bank stated it has 26,753 shares. Teacher Retirement Of Texas reported 0.01% of its portfolio in Seattle Genetics, Inc. (NASDAQ:SGEN). First Hawaiian Fincl Bank has invested 0% in Seattle Genetics, Inc. (NASDAQ:SGEN). Northern Trust has 0.01% invested in Seattle Genetics, Inc. (NASDAQ:SGEN) for 613,684 shares.

Since August 21, 2018, it had 0 buys, and 16 selling transactions for $13.81 million activity. Another trade for 5,000 shares valued at $310,718 was sold by HIMES VAUGHN B. $402,856 worth of stock was sold by SIMPSON TODD E on Monday, August 27. On Thursday, November 29 Cline Darren S sold $440,160 worth of Seattle Genetics, Inc. (NASDAQ:SGEN) or 7,000 shares. GRYSKA DAVID W sold 5,000 shares worth $325,200. $306,058 worth of stock was sold by LIU JEAN I on Monday, August 27.

Analysts expect Seattle Genetics, Inc. (NASDAQ:SGEN) to report $-0.38 EPS on February, 5.They anticipate $0.03 EPS change or 7.32 % from last quarter’s $-0.41 EPS. After having $-0.27 EPS previously, Seattle Genetics, Inc.’s analysts see 40.74 % EPS growth. The stock decreased 1.11% or $0.79 during the last trading session, reaching $70.62. About 640,357 shares traded. Seattle Genetics, Inc. (NASDAQ:SGEN) has risen 5.90% since January 14, 2018 and is uptrending. It has outperformed by 5.90% the S&P500.

Seattle Genetics, Inc. (NASDAQ:SGEN) Ratings Coverage

Among 4 analysts covering Seattle Genetics (NASDAQ:SGEN), 3 have Buy rating, 0 Sell and 1 Hold. Therefore 75% are positive. Seattle Genetics had 5 analyst reports since July 27, 2018 according to SRatingsIntel. The stock of Seattle Genetics, Inc. (NASDAQ:SGEN) has “Overweight” rating given on Friday, July 27 by JP Morgan. As per Friday, October 26, the company rating was maintained by Barclays Capital. The firm has “Overweight” rating given on Wednesday, October 3 by Barclays Capital. On Tuesday, November 27 the stock rating was maintained by Piper Jaffray with “Hold”.

Seattle Genetics, Inc., a biotechnology company, develops and commercializes targeted therapies to treat cancer worldwide. The company has market cap of $11.31 billion. It markets ADCETRIS, an antibody-drug conjugate for relapsed Hodgkin lymphoma and relapsed systemic anaplastic large cell lymphoma. It currently has negative earnings. The firm also develops SGN-CD33A that is in Phase III clinical trial to evaluate SGN-CD33A in combination with hypomethylating agents in previously untreated older patients, as well as in Phase 1/2 clinical trial for patients with relapsed or refractory acute myeloid leukemia ; ASG-22ME, which is in Phase I clinical trial for Nectin-4-positive solid tumors, including bladder cancer; SGN-LIV1A that is in Phase 1 clinical trial for patients with LIV-1-positive metastatic breast cancer; and SGN-CD19A, which is in Phase II clinical trial for patients with relapsed DLBCL, as well as in Phase II trial for patients with newly diagnosed DLBCL.

More notable recent Seattle Genetics, Inc. (NASDAQ:SGEN) news were published by: Investorplace.com which released: “5 Biotech Stocks That Could Face M&A Next! – Investorplace.com” on January 10, 2019, also Seekingalpha.com with their article: “Cancer Research Highlight: Seattle Genetics Moves The Chains In T-Cell Lymphoma – Seeking Alpha” published on October 04, 2018, Seekingalpha.com published: “Piper softens view on Gilead in analyst healthcare action – Seeking Alpha” on October 26, 2018. More interesting news about Seattle Genetics, Inc. (NASDAQ:SGEN) were released by: Seekingalpha.com and their article: “Don’t Sell Axon Enterprise – Cramer’s Lightning Round (7/11/18) – Seeking Alpha” published on July 12, 2018 as well as Fool.com‘s news article titled: “Why Seattle Genetics Jumped Higher Today – The Motley Fool” with publication date: April 27, 2018.

Seattle Genetics, Inc. (NASDAQ:SGEN) Institutional Positions Chart

(adsbygoogle = window.adsbygoogle || []).push({});

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.